Diffusion and perfusion MRI for prediction of HCC response to neoadjuvant immunotherapy

Abstract

Neoadjuvant immunotherapy has the potential to decrease the risk of hepatocellular carcinoma (HCC) recurrence post resection. The objectives of this study were to assess the value of pre-treatment MRI parameters for prediction of HCC immunophenotype and response in a cohort of patients undergoing neoadjuvant immunotherapy prior to liver resection. We hypothesize that diffusion and perfusion MRI can predict HCC response to neoadjuvant immunotherapy. It was observed that abundant of TILs decreases ADC in tumors. Moreover, uptake rate is higher in highly necrotic tumors.